Olanzapine (Zyprexa Relprevv) vs Quetiapine (Seroquel XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Quetiapine (Seroquel XR)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Weak signal

NCT00640601 · Phase 3 · completed

This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)

Result source: NCT00640601

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa Relprevv)Quetiapine (Seroquel XR)
PANSS total, change—Not posted · NCT00088491-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562
CGI-S, change-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562
PANSS response—Not posted · NCT0008849162.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Not posted · NCT0008849115.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489—Not posted · NCT00159770

PANSS total, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Quetiapine (Seroquel XR)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562

CGI-S, change

Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
Quetiapine (Seroquel XR)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562

PANSS response

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Quetiapine (Seroquel XR)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Quetiapine (Seroquel XR)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
Quetiapine (Seroquel XR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Olanzapine (Zyprexa Relprevv): 9 of 9 rows · Quetiapine (Seroquel XR): 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa Relprevv)
Rows use multiple source trials
Quetiapine (Seroquel XR)
Rows use multiple source trials
CGI-S
absolute change · score
No placebo or comparator arm
-0.17 score @ 313wka,b,c
NCT00088465 · Phase 3 · registry result, not featured evidence
0.51 score @ 24wka,b,c
NCT00640601 · Phase 3
PANSS General Psychopathology
absolute change · score
No placebo or comparator arm
0.19 score @ 330wkd,a,b,e
NCT00088465 · Phase 3 · registry result, not featured evidence
-13.2 score @ 8.14wkd,a,b,e
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Negative
absolute change · score
No placebo or comparator arm
-0.08 score @ 330wka,b,f
NCT00088465 · Phase 3 · registry result, not featured evidence
3.67 score @ 24wka,b,f
NCT00640601 · Phase 3
PANSS Positive
absolute change · score
No placebo or comparator arm
0.21 score @ 330wka,b,f
NCT00088465 · Phase 3 · registry result, not featured evidence
2.36 score @ 24wka,b,f
NCT00640601 · Phase 3
PANSS Total
absolute change · score
No placebo or comparator arm
0.3 score @ 330wka,b,f
NCT00088465 · Phase 3 · registry result, not featured evidence
10.95 score @ 24wka,b,f
NCT00640601 · Phase 3
Dropout rate
54.9%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
38%g
NCT00640601 · Phase 3
show 7 more results
16.5%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
20%
NCT00954122 · Phase 4 · registry result, not featured evidence
30.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
9.8%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
14.6%g
NCT00640601 · Phase 3
show 7 more results
7.3%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
4.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Serious AEs
9.5%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
11.2%g
NCT00640601 · Phase 3
show 7 more results
3.7%
NCT00640562 · Phase 3
0%Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
0%
NCT00779506 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
g
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
g
somnolence 18%
dizziness 14.6%
sedation 14.2%
NCT00640601 · Phase 3
show 5 more results
somnolence 5.5%
dry months 4.6%
hypotension 4.6%
NCT00640562 · Phase 3
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
constipation 25.5%
insomnia 23.4%
sedation 12.8%
NCT00779506 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 24 weeks versus 313 weeks.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. eAssessment timepoints differ: 8.14 weeks versus 330 weeks.
  6. fAssessment timepoints differ: 24 weeks versus 330 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 9 further endpoints in the CSV export.

Quetiapine (Seroquel XR)

Clinical Benefit 56.88% (n=295) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-CB 1.41 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
GAS 5.54 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-I 0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
2.4 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
SOFAS 6.45 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CDSS 7.31 vs 5.53 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
HAM-D -29.83 vs -23.02 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
PANSS Total 102.26 vs 100.51 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
show 1 more result
-24 vs -15.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
CGI-I 91 vs 88 Risperidone score @ 12wk
absolute value · score
NCT00640562 · Phase 3
show 1 more result
2.5 vs 3 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
Attention Composite Z-score 0.002 standardised units
absolute change · standardised units
No placebo or comparator arm
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.098 standardised units
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
N-Back Task 2.875 score
absolute change · score
No placebo or comparator arm
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
2.897 score
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
PANSS-EC -7.5 score @ 3wk
absolute change · score
No placebo or comparator arm
NCT00954122 · Phase 4 · registry result, not featured evidence
show 1 more result
-33.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Quetiapine (Seroquel XR)'s landscape